Spears Abacus Advisors LLC Vertex Pharmaceuticals Inc Transaction History
Spears Abacus Advisors LLC
- $4.12 Billion
- Q1 2025
A detailed history of Spears Abacus Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Spears Abacus Advisors LLC holds 1,909 shares of VRTX stock, worth $714,844. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,909
Previous 1,941
1.65%
Holding current value
$714,844
Previous $781,000
18.44%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,813Shares Held
232MCall Options Held
1.51MPut Options Held
1.09M-
Capital World Investors Los Angeles, CA28.5MShares$10.7 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$8.98 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$7.98 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$5.44 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.41 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $96.1B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...